Video

Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer

Author(s):

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Ritu Salani, MD, MBA, director of the Division of Gynecologic Oncology, professor of Obstetrics and Gynecology, University of California, Los Angeles, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Combination immunotherapy and PARP inhibitors capitalize on DNA damage repair and priming the immune system and in turn, the immunotherapy can be more active in tumors that are not typically considered immunogenic, Salani says. Overall, immunotherapy can exploit a deficiency to make it opportunistic. 

Preliminary data observed in phase 2 clinical trials have suggested utility with this combination approach, Salani explains.

Moreover, adding VEGF inhibitors, such as bevacizumab (Avastin), to this combination strategy could enhance synergistic activity of this treatment for patients with ovarian cancer independent of BRCA, homologous recombination deficiency, or PD-1/PD-L1 status, Salani concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP